Definium Therapeutics (DFTX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

DFTX · Stock Price

USD 23.20+17.05 (+277.24%)

Market Cap: $2.4B

Historical price data

Overview

Definium Therapeutics, formerly MindMed, is a science-led biotech company dedicated to developing next-generation psychedelic therapeutics for serious psychiatric conditions. Its strategy centers on pharmaceutical optimization of classical compounds like LSD and MDMA to create proprietary, scalable treatments. The company's lead asset, DT120, is in multiple Phase 3 trials for Generalized Anxiety Disorder and Major Depressive Disorder, positioning it as a frontrunner in the emerging psychedelic medicine sector. Definium aims to redefine treatment success by targeting the root causes of disorders, moving beyond symptom management to enable functional recovery.

PsychiatryMental Health

Technology Platform

A proprietary platform focused on the pharmaceutical optimization of classical psychedelic compounds, including advanced formulation (e.g., ODT), enantiomeric selection, and integrated therapeutic protocol development to create scalable, consistent medicines.

Pipeline

7

7 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
MM120 (LSD D-Tartrate)	Major Depressive Disorder	Phase 3
MM120 (LSD D-Tartrate)	Generalized Anxiety Disorder	Phase 3
MM120 (LSD D-Tartrate)	Generalized Anxiety Disorder	Phase 3
MM120	ADHD	Phase 2
MM120	Anxiety Generalized	Phase 2

Opportunities

Definium's lead program, DT120, targets the massive, underserved markets of MDD and GAD (~67M combined U.S.

adults) where current treatments have high failure rates.

Success in Phase 3 could lead to a paradigm-shifting, first-in-class therapy with premium pricing.

Additionally, DT402 addresses a completely unmet need in Autism Spectrum Disorder, a greenfield market with no approved drugs for core social symptoms.

Risk Factors

The company faces high binary risk from its pivotal Phase 3 trial readouts.

Regulatory hurdles around the controlled substance status of its compounds could delay commercialization.

Significant future capital raises may dilute shareholders, and establishing a scalable, reimbursable treatment model involving psychological support presents a major commercial execution challenge.

Competitive Landscape

Definium competes in the emerging psychedelic medicine sector against companies like Compass Pathways (psilocybin for TRD) and GH Research (5-MeO-DMT). Its primary advantages are the advanced Phase 3 status of DT120 for broad MDD/GAD indications and its pharmaceutical optimization platform. It also faces indirect competition from large pharma companies developing novel, non-psychedelic CNS drugs.

More companies in United States →